Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Nsaka

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Cephalalgia : an International Journal of Headache|February 14, 2023
Hypnic Headache - What do we know in 2022?Diana Lindner, Armin Scheffler, Michael Nsaka, et al.
The Journal of Headache and Pain|May 10, 2022
Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world studyHannah Schenk, Dagny Holle, Michael Nsaka, et al.
The Journal of Headache and Pain|July 5, 2020
Erenumab in highly therapy-refractory migraine patients: First German real-world evidenceArmin Scheffler, Olga Messel, Sebastian Wurthmann, et al.
The Journal of Headache and Pain|September 21, 2021
CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experienceArmin Scheffler, Hannah Schenk, Sebastian Wurthmann, et al.
Brain and Behavior|June 10, 2022
Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodiesMichael Nsaka, Armin Scheffler, Sebastian Wurthmann, et al.
European Journal of Neurology|August 11, 2021
Response to the Letter to the Editor by Arshad and Bronstein "Motion perception in vestibular migraine"Sebastian Wurthmann, Steffen Naegel, Michael Nsaka, et al.
European Journal of Neurology|April 29, 2021
Sensitized rotatory motion perception and increased susceptibility to motion sickness in vestibular migraine: A cross-sectional studySebastian Wurthmann, Steffen Naegel, Miriam Roesner, et al.
BMC Neurology|October 13, 2021
Reduced vestibular perception thresholds in persistent postural-perceptual dizziness- a cross-sectional studySebastian Wurthmann, Dagny Holle, Mark Obermann, et al.
The Journal of Headache and Pain|July 4, 2024
Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache - a retrospective real-world analysisArmin Scheffler, Jale Basten, Lennart Menzel, et al.
The Journal of Headache and Pain|May 16, 2024
Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: a multicentre retrospective real-world analysis from GermanyArmin Scheffler, Pauline Wenzel, Merle Bendig, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Cephalalgia : an International Journal of Headache|February 14, 2023
Hypnic Headache - What do we know in 2022?Diana Lindner, Armin Scheffler, Michael Nsaka, et al.
The Journal of Headache and Pain|May 10, 2022
Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world studyHannah Schenk, Dagny Holle, Michael Nsaka, et al.
The Journal of Headache and Pain|July 5, 2020
Erenumab in highly therapy-refractory migraine patients: First German real-world evidenceArmin Scheffler, Olga Messel, Sebastian Wurthmann, et al.
The Journal of Headache and Pain|September 21, 2021
CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experienceArmin Scheffler, Hannah Schenk, Sebastian Wurthmann, et al.
Brain and Behavior|June 10, 2022
Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodiesMichael Nsaka, Armin Scheffler, Sebastian Wurthmann, et al.
European Journal of Neurology|August 11, 2021
Response to the Letter to the Editor by Arshad and Bronstein "Motion perception in vestibular migraine"Sebastian Wurthmann, Steffen Naegel, Michael Nsaka, et al.
European Journal of Neurology|April 29, 2021
Sensitized rotatory motion perception and increased susceptibility to motion sickness in vestibular migraine: A cross-sectional studySebastian Wurthmann, Steffen Naegel, Miriam Roesner, et al.
BMC Neurology|October 13, 2021
Reduced vestibular perception thresholds in persistent postural-perceptual dizziness- a cross-sectional studySebastian Wurthmann, Dagny Holle, Mark Obermann, et al.
The Journal of Headache and Pain|July 4, 2024
Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache - a retrospective real-world analysisArmin Scheffler, Jale Basten, Lennart Menzel, et al.
The Journal of Headache and Pain|May 16, 2024
Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: a multicentre retrospective real-world analysis from GermanyArmin Scheffler, Pauline Wenzel, Merle Bendig, et al.
Pageof 1